Saptagir Laboratories to manufacture Remdesivir for Jubilant Generics

Hyderabad: Hyderabad-based bulk drugs and intermediates firm Saptagir Laboratories, part of the Rs 900 crore Saptagir Group, has entered into an exclusive agreement with Jubilant Generics, a Jubilant Life Sciences company, to manufacture intermediates and bulk drugs for intravenous administered drug ‘Remdesivir’.

The drug will be produced at its Hyderabad WHO GMP certified sterile drug product manufacturing plant.

Announcing this strategic partnership Shilpa Reddy, MD, Saptagir Laboratories stated, “This partnership is timely and in line with our strategic growth plans for the company. Our foray into bulk drug manufacturing will open new revenue streams, backed by our extensive global customer base spanning over 50 countries with an array of products targeted at the fast-growing health and wellness segment.”

Mahesh Reddy, chairman, Saptagir Group said, “We have had several successes in product development in molecules that were previously only manufactured in China. This partnership meets the need of our multinational customers who approve India as a strong second source for products beyond China.”

“With the new investment of Rs 75 crores in the pharma plant at Hyderabad we will further grow our presence in the health and wellness business,” he added.

Remdesivir is an experimental antiviral drug developed by Gilead Sciences, as a course of treatment for COVID-19. Gilead entered into a non-exclusive licensing agreement with Jubilant Life Sciences for distribution to 127 countries.

Following this, Jubilant Life Sciences through its subsidiary Jubilant Generics has entered an exclusive agreement with Saptagir Laboratories to manufacture Remdesivir.

Remdesivir has been approved for emergency use in countries such as Singapore, The USA and India, as well as permitted for use in severe cases in Japan, the EU, and Australia, for the treatment of COVID-19. The market for Remdesivir according to Gilead Life Sciences, the innovator, is estimated to be $2.3 billion for this year.

Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .